2,3-Dihydrospiro[indene-1,4'-piperidin]-2-ol | 473929-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2,3-Dihydrospiro[indene-1,4'-piperidin]-2-ol
• 英文别名: spiro[1,2-dihydroindene-3,4'-piperidine]-2-ol
• CAS: 473929-12-3
• 化学式: C₁₃H₁₇NO
• 分子量: 203.284
• InChiKey: DBCKHYVIUIDGOH-UHFFFAOYSA-N

物化性质

• 沸点：
  358.4±42.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-Dihydrospiro[indene-1,4'-piperidin]-2-ol 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-amino-N-[(2R)-1-(2-hydroxyspiro[1,2-dihydroindene-3,4'-piperidine]-1'-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide;hydrochloride
  参考文献：
  名称：

  The synthesis and activity of spiroindane growth hormone secretagogues

  摘要：

  The synthesis and activities of a series of spiroindane growth hormone secretagogues is reported. Modification of the benzylic position of the spiroindane has resulted in a dramatic increase in potency resulting in subnanomolar peptidomimetic growth hormone secretagogues. In vivo data demonstrating the good oral activity of these analogs is reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00075-9
• 作为产物：
  描述：

  1H-螺[茚-1,4-哌啶]-1-羧酸叔丁酯 在 sodium hydroxide 、 硼烷 、 双氧水 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2,3-Dihydrospiro[indene-1,4'-piperidin]-2-ol
  参考文献：
  名称：

  The synthesis and activity of spiroindane growth hormone secretagogues

  摘要：

  The synthesis and activities of a series of spiroindane growth hormone secretagogues is reported. Modification of the benzylic position of the spiroindane has resulted in a dramatic increase in potency resulting in subnanomolar peptidomimetic growth hormone secretagogues. In vivo data demonstrating the good oral activity of these analogs is reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00075-9

文献信息

• [EN] NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE SHP2
  申请人：JACOBIO PHARMACEUTICALS CO LTD

  公开号：WO2018172984A1

  公开（公告）日：2018-09-27

  This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

  这项发明涉及某些新颖的吡嗪衍生物（化学式I）作为SHP2抑制剂，其化学式如下，以及它们的合成以及用于治疗SHP2介导的疾病的用途。更具体地，这项发明涉及融合杂环基衍生物，可用作SHP2的抑制剂，生产这类化合物的方法以及治疗SHP2介导的疾病的方法。
• Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20050277659A1

  公开（公告）日：2005-12-15

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like; and n represents an integer 0, 1 or 2. These compounds have ORL 1 -receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了式（I）的化合物：或其药学上可接受的酯，或其药学上可接受的盐，其中R1和R2分别独立地表示氢原子或类似物；R3表示具有6至10个环原子或类似物的芳基基团；X表示氧原子或类似物；Y表示氧原子或类似物；n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们可用于治疗疾病或病症，例如疼痛，各种中枢神经系统疾病等。
• Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20070197500A1

  公开（公告）日：2007-08-23

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents a hydrogen atom, or the like; R 4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R 5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了以下化合物的公式(I)、其药学上可接受的酯或其药学上可接受的盐，其中R1和R2独立地表示氢原子或类似物；R3表示氢原子或类似物；R4表示氢原子或类似物；(公式II)代表以下之一或类似物；R5表示具有6至10个环原子的芳基基团或类似物；X表示氧原子或类似物；Y表示氧原子或类似物，n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们对于治疗疾病或症状，如疼痛、各种中枢神经系统疾病等非常有用。
• ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST
  申请人：Pfizer Japan, Inc.

  公开号：EP1732893A2

  公开（公告）日：2006-12-20
• NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：EP3601239A1

  公开（公告）日：2020-02-05